Seminars in Arthritis and Rheumatism Seminars in Arthritis and Rheumatism RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial
Giant cell arteritis (GCA) is the most common form of systemic vasculitis. Glucocorticoids are an effective treatment but have significant adverse events and relapses are common. Interleukins 12 (IL-12) and 23 (IL-23) stimulate TH1 and TH17 responses and are implicated in the pathogenesis of GCA. The aim of this study was to evaluate the efficacy and safety of IL-12/23 blockade with ustekinumab in GCA. (Source: Seminars in Arthritis and Rheumatism)
Source: Seminars in Arthritis and Rheumatism - April 21, 2018 Category: Rheumatology Authors: Richard Conway, Lorraine O ’Neill, Phil Gallagher, Geraldine M. McCarthy, Conor C. Murphy, Douglas J. Veale, Ursula Fearon, Eamonn S. Molloy Source Type: research

Ustekinumab for Refractory Giant Cell Arteritis: A Prospective 52-week Trial ☆
Giant cell arteritis (GCA) is the most common form of systemic vasculitis. Glucocorticoids are an effective treatment but have significant adverse events and relapses are common. Interleukins 12 (IL-12) and 23 (IL-23) stimulate TH1 and TH17 responses and are i implicated in the pathogenesis of GCA. The aim of this study was to evaluate the efficacy and safety of IL-12/23 blockade with ustekinumab in GCA. (Source: Seminars in Arthritis and Rheumatism)
Source: Seminars in Arthritis and Rheumatism - April 21, 2018 Category: Rheumatology Authors: Richard Conway, Lorraine O ’Neill, Phil Gallagher, Geraldine M McCarthy, Conor C Murphy, Douglas J Veale, Ursula Fearon, Eamonn S Molloy Source Type: research

Biologics in SAPHO syndrome: A systematic review
The SAPHO syndrome is a relatively rare clinical entity characterized by a wide range of dermatological and musculoskeletal manifestations. Biologics have been used in cases refractory to conventional treatment. (Source: Seminars in Arthritis and Rheumatism)
Source: Seminars in Arthritis and Rheumatism - April 17, 2018 Category: Rheumatology Authors: Dimitrios Daoussis, Georgia Konstantopoulou, Pantelis Kraniotis, Lazaros Sakkas, Stamatis-Nick Liossis Source Type: research

Biologics in SAPHO syndrome. A systematic review
The SAPHO syndrome is a relatively rare clinical entity characterized by a wide range of dermatological and musculoskeletal manifestations. Biologics have been used in cases refractory to conventional treatment. (Source: Seminars in Arthritis and Rheumatism)
Source: Seminars in Arthritis and Rheumatism - April 17, 2018 Category: Rheumatology Authors: Dimitrios Daoussis, Georgia Konstantopoulou, Pantelis Kraniotis, Lazaros Sakkas, Stamatis-Nick Liossis Source Type: research

Long-Term Effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in Primary Antiphospholipid Syndrome
To investigate the long term effect of B-cell depletion therapy with Rituximab (RTX) alone as rescue therapy in primary antiphospholipid syndrome (PAPS) patients with severe thrombocytopenia. (Source: Seminars in Arthritis and Rheumatism)
Source: Seminars in Arthritis and Rheumatism - April 11, 2018 Category: Rheumatology Authors: Savino Sciascia, Massimo Radin, Irene Cecchi, Elena Rubini, Mario Bazzan, Dario Roccatello Source Type: research

Comment on: Efficacy of Curcumin and Boswellia for Knee Osteoarthritis: Systematic Review and Meta-Analysis
Dear Sir, (Source: Seminars in Arthritis and Rheumatism)
Source: Seminars in Arthritis and Rheumatism - April 11, 2018 Category: Rheumatology Authors: Ali Mobasheri, Yves Henrotin Source Type: research

Long-Term Effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in Primary Antiphospholipid Syndrome
To investigate the long term effect of B-cell depletion therapy with Rituximab (RTX) alone as rescue therapy in primary antiphospholipid syndrome (PAPS) patients with severe thrombocytopenia. (Source: Seminars in Arthritis and Rheumatism)
Source: Seminars in Arthritis and Rheumatism - April 11, 2018 Category: Rheumatology Authors: Savino Sciascia, Massimo Radin, Irene Cecchi, Elena Rubini, Mario Bazzan, Dario Roccatello Source Type: research

Comment on: Efficacy of Curcumin and Boswellia for Knee Osteoarthritis: Systematic Review and Meta-Analysis
Dear Sir, (Source: Seminars in Arthritis and Rheumatism)
Source: Seminars in Arthritis and Rheumatism - April 11, 2018 Category: Rheumatology Authors: Ali Mobasheri, Yves Henrotin Source Type: research

Practical suggestions on intravenous iloprost in Raynaud ’s phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus
Systemic sclerosis (SSc) is an autoimmune chronic disease characterized by vascular impairment, immune dysfunction and collagen deposition. Raynaud ’s phenomenon (RP) and digital ulcers (DU) are prominent features of SSc. Intravenous (IV) iloprost (ILO), according to the recently updated EULAR recommendations, is indicated for RP after failure of oral therapy. Moreover, IV ILO could be useful in DU healing. IV ILO is currently available mainl y on the European market approved for RP secondary to SSc with 3–5 days infusion cycle. (Source: Seminars in Arthritis and Rheumatism)
Source: Seminars in Arthritis and Rheumatism - April 4, 2018 Category: Rheumatology Authors: Francesca Ingegnoli, Tommaso Schioppo, Yannick Allanore, Roberto Caporali, Michele Colaci, Oliver Distler, Daniel E. Furst, Nicolas Hunzelmann, Florenzo Iannone, Dinesh Khanna, Marco Matucci-Cerinic Source Type: research

Practical Suggestions on Intravenous Iloprost in Raynaud's Phenomenon and Digital Ulcer Secondary to Systemic Sclerosis: Systematic Literature Review And Expert Consensus
Systemic sclerosis (SSc) is an autoimmune chronic disease characterized by vascular impairment, immune dysfunction and collagen deposition. Raynaud's phenomenon (RP) and digital ulcers (DU) are prominent features of SSc. Intravenous (IV) iloprost (ILO), according to the recently updated EULAR recommendations, is indicated for RP after failure of oral therapy. Moreover, IV ILO could be useful in DU healing. IV ILO is currently available mainly on the European market approved for RP secondary to SSc with 3 –5 days infusion cycle. (Source: Seminars in Arthritis and Rheumatism)
Source: Seminars in Arthritis and Rheumatism - April 4, 2018 Category: Rheumatology Authors: Francesca Ingegnoli, Tommaso Schioppo, Yannick Allanore, Roberto Caporali, Michele Colaci, Oliver Distler, Daniel E. Furst, Nicolas Hunzelmann, Florenzo Iannone, Dinesh Khanna, Marco Matucci-Cerinic Source Type: research

Editorial Board
(Source: Seminars in Arthritis and Rheumatism)
Source: Seminars in Arthritis and Rheumatism - April 1, 2018 Category: Rheumatology Source Type: research

High Rates of Tuberculin Skin Test Positivity due to Methotrexate Therapy: False Positive Results?
Latent tuberculosis infection (LTBI) is the most prevalent form of tuberculosis worldwide[1]. Screening for LTBI is recommended before the initiation of tumor necrosis factor (TNF) antagonist therapy[2,3], which is associated with an increased risk of tuberculosis reactivation in LTBI[4 –7]. Treatment for LTBI greatly reduces the risk of developing active disease, but potential side effects can occur, including hepatotoxicity[8]. A substantial reduction in the rate of tuberculosis reactivation in patients receiving anti-TNF therapy has been observed after LTBI screening and preve ntion interventions were implemented[9]. ...
Source: Seminars in Arthritis and Rheumatism - March 29, 2018 Category: Rheumatology Authors: Miguel Arias-Guill én, Marta M. Sánchez Menéndez, Mercedes Alperi, Sabino Riestra-Menéndez, María Teresa González Budiño, Marta María García-Clemente, Susana Martínez-González, Ana Isabel Enríquez, Rebeca Alonso-Arias, Juan José Palacios Guti Source Type: research